Lionel Adès

Lionel Adès is a Professor of Hematology at Hôpital Saint-Louis, affiliated with Université de Paris, where he has maintained continuous employment since January 1997. His clinical and research activities focus on myeloid malignancies, particularly myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and acute promyelocytic leukemia.

Dr. Adès' research interests center on the molecular characterization of myelodysplastic syndromes, risk stratification systems, and novel therapeutic approaches for high-risk hematologic malignancies. His work prominently features investigations into TP53-mutated diseases, VEXAS syndrome (a recently described entity involving UBA1 mutations), and treatment response prediction using genomic markers. He has made significant contributions to understanding the role of specific somatic mutations in treatment response and disease progression.

Analysis of his recent publication record (2023-2025) reveals a strong focus on precision medicine approaches in myeloid malignancies. His work spans clinical trials of novel agents like eprenetapopt for TP53-mutated diseases, real-world evidence studies of luspatercept in ring sideroblast-positive MDS, and innovative approaches to risk assessment including the IPSS-M scoring system. He frequently collaborates with international consortia including the Groupe Francophone des Myélodysplasies (GFM) and European organizations like EBMT and European LeukemiaNet.

Dr. Adès serves as an active peer reviewer for major hematology journals, with documented reviews for Leukemia (8 reviews), Blood reviews, Annals of hematology, and others. His publication record demonstrates leadership in developing clinical guidelines and consensus statements, particularly through his involvement with European expert panels. While specific grant information isn't provided in the text, his numerous multi-center clinical trials suggest substantial research funding support.

His laboratory work appears to include investigations into the bone marrow microenvironment, as evidenced by publications on 3D artificial marrow organoid systems for studying hematopoiesis. He collaborates extensively with researchers across Europe and maintains active involvement in both clinical care and translational research, bridging the gap between laboratory discoveries and patient applications.